Catalent Pharma Solutions has entered into a contract with Biota Pharmaceuticals, Inc. to provide filling and packaging of clinical trial materials of laninamivir octanoate, an inhaled long-acting neuraminidase inhibitor in development for the treatment of influenza A and B viruses.   In 2012, Catalent began working on the inhalation formulation feasibility studies, device filling, and analytical support from its facilities in Research Triangle Park (RTP), NC. Catalent will provide clinical pack...